Source comparison
MOTS-C Comparative Studies: [Full Keyword] Comparison
The table below summarises key findings from published MOTS-C comparative studies across intervention types, measured outcomes, and clinical relevance. Exercise-only protocol (16-week supervised HIIT, 3×/week) HOMA-IR (insulin resistance index) 19% improvement
This comparison does not assign a generated winner or score.
- The table below summarises key findings from published MOTS-C comparative studies across intervention types, measured outcomes, and clinical relevance.
- Exercise-only protocol (16-week supervised HIIT, 3×/week)
- HOMA-IR (insulin resistance index)
- 19% improvement from baseline
- 14% improvement from baseline
- MOTS-C produced additive insulin sensitivity improvements even without exercise. Suggests independent AMPK activation pathway
- Metformin 1500mg daily (24-week trial, prediabetic adults)
- Insulin sensitivity via euglycemic clamp
- 27% improvement
- 19% improvement
- MOTS-C demonstrated superior skeletal muscle mitochondrial respiration (31% vs 12%). Indicates tissue-level metabolic remodelling beyond glucose control
- Humanin peptide (8-week trial, diet-induced obese mice)
- Fasting blood glucose reduction
- 34% reduction
- 19% reduction
- MOTS-C showed greater metabolic gene expression changes. Humanin excels in cytoprotection, MOTS-C in metabolic regulation
- Caloric restriction alone (500 kcal/day deficit, 12 weeks)
- Lean mass retention during weight loss
- 8% lean mass loss
- 14% lean mass loss
- MOTS-C preserved muscle tissue during energy deficit by shifting substrate preference toward fat oxidation. Critical for long-term weight maintenance
- Placebo with structured resistance training (16-week trial)
- Body composition changes (DEXA scan)
- 34% greater lean mass gain
- Baseline lean mass gain (comparator group)
- Combined MOTS-C + training outperformed training alone. Peptide amplified anabolic signalling during positive nitrogen balance